{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T11:10:36Z","timestamp":1778497836760,"version":"3.51.4"},"reference-count":82,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","award":["25343"],"award-info":[{"award-number":["25343"]}],"id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007475","name":"Canadian Dermatology Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100007475","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Canadian Institutes for Health Research","award":["428712"],"award-info":[{"award-number":["428712"]}]},{"name":"Canadian Institutes for Health Research","award":["426655"],"award-info":[{"award-number":["426655"]}]},{"name":"Fonds de la recherche du Qu\u00e9bec \u2013 Sant\u00e9 grants","award":["34753"],"award-info":[{"award-number":["34753"]}]},{"name":"Fonds de la recherche du Qu\u00e9bec \u2013 Sant\u00e9 grants","award":["36769"],"award-info":[{"award-number":["36769"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Targeted therapy has been developed through an in-depth understanding of molecular pathways involved in the pathogenesis of melanoma. Approximately ~50% of patients with melanoma have tumors that harbor a mutation of the BRAF oncogene. Certain clinical features have been identified in BRAF-mutated melanomas (primary lesions located on the trunk, diagnosed in patients &lt;50, visibly pigmented tumors and, at times, with ulceration or specific dermatoscopic features). While BRAF mutation testing is recommended for stage III\u2013IV melanoma, guidelines differ in recommending mutation testing in stage II melanoma patients. To fully benefit from these treatment options and avoid delays in therapy initiation, advanced melanoma patients harboring a BRAF mutation must be identified accurately and quickly. To achieve this, clear definition and implementation of BRAF reflex testing criteria\/methods in melanoma should be established so that patients with advanced melanoma can arrive to their first medical oncology appointment with a known biomarker status. Reflex testing has proven effective for a variety of cancers in selecting therapies and driving other medical decisions. We overview the pathophysiology, clinical presentation of BRAF-mutated melanoma, current guidelines, and present recommendations on BRAF mutation testing. We propose that reflex BRAF testing should be performed for every melanoma patient with stages \u2265IIB.<\/jats:p>","DOI":"10.3390\/cancers13092282","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T10:49:51Z","timestamp":1620643791000},"page":"2282","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Defining the Criteria for Reflex Testing for BRAF Mutations in Cutaneous Melanoma Patients"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9351-8487","authenticated-orcid":false,"given":"Sarah","family":"Zhou","sequence":"first","affiliation":[{"name":"Division of Dermatology, McGill University, Montreal, QC H3A 0G4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Sikorski","sequence":"additional","affiliation":[{"name":"Division of Dermatology, McGill University, Montreal, QC H3A 0G4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honghao","family":"Xu","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Laval University, Quebec City, QC G1V 0A6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrei","family":"Zubarev","sequence":"additional","affiliation":[{"name":"Division of Dermatology, McGill University, Montreal, QC H3A 0G4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May","family":"Chergui","sequence":"additional","affiliation":[{"name":"Department of Pathology, McGill University, Montreal, QC H3A 0G4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9033-2302","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Lagac\u00e9","sequence":"additional","affiliation":[{"name":"Division of Dermatology, McGill University, Montreal, QC H3A 0G4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Wilson H.","family":"Miller","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Oncology, McGill University, Montreal, QC H3A 0G4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Redpath","sequence":"additional","affiliation":[{"name":"Department of Pathology, McGill University, Montreal, QC H3A 0G4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Ghazal","sequence":"additional","affiliation":[{"name":"Division of Dermatology, McGill University, Montreal, QC H3A 0G4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9840-7057","authenticated-orcid":false,"given":"Marcus O.","family":"Butler","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, Department of Medical Oncology and Hematology, University of Toronto, Toronto, ON M5G 2C1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa M.","family":"Petrella","sequence":"additional","affiliation":[{"name":"Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON M4N 3M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00ebl","family":"Claveau","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Laval University, Quebec City, QC G1V 0A6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0419-3511","authenticated-orcid":false,"given":"Carolyn","family":"Nessim","sequence":"additional","affiliation":[{"name":"Division of General Surgery, University of Ottawa, Ottawa, ON K1N 6N5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6990-8680","authenticated-orcid":false,"given":"Thomas G.","family":"Salopek","sequence":"additional","affiliation":[{"name":"Division of Dermatology, University of Alberta, Edmonton, AB T6G 2R3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Gniadecki","sequence":"additional","affiliation":[{"name":"Division of Dermatology, University of Alberta, Edmonton, AB T6G 2R3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0562-4675","authenticated-orcid":false,"given":"Ivan V.","family":"Litvinov","sequence":"additional","affiliation":[{"name":"Division of Dermatology, McGill University, Montreal, QC H3A 0G4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaad.2018.07.041","article-title":"Cutaneous malignant melanoma incidence and mortality trends in Canada: A comprehensive population-based study","volume":"80","author":"Ghazawi","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/1203475419852048","article-title":"Incidence, Mortality, and Spatiotemporal Distribution of Cutaneous Malignant Melanoma Cases Across Canada","volume":"23","author":"Ghazawi","year":"2019","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000507617","article-title":"Geographic Variations in Cutaneous Melanoma Distribution in the Russian Federation","volume":"236","author":"Muntyanu","year":"2020","journal-title":"Dermatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jaad.2018.10.055","article-title":"Trends in incidence of cutaneous malignant melanoma in Canada: 1992-2010 versus 2011-2015","volume":"80","author":"Ghazawi","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_5","first-page":"87","article-title":"Canadian perspective on the clinical management of metastatic melanoma","volume":"70","author":"Petrella","year":"2012","journal-title":"Lung"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_7","first-page":"214","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nat. Cell Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"626129","DOI":"10.3389\/fonc.2020.626129","article-title":"Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities","volume":"10","author":"Eddy","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11864-021-00818-3","article-title":"BRAF Heterogeneity in Melanoma","volume":"22","author":"Ito","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"adv00138","DOI":"10.2340\/00015555-3493","article-title":"Melanoma Genomics","volume":"100","author":"Bishop","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_11","first-page":"96","article-title":"The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma","volume":"38","author":"McCain","year":"2013","journal-title":"Pharm. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc.2016.37","article-title":"From melanocytes to melanomas","volume":"16","author":"Shain","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1002\/cncr.28864","article-title":"The MAPK pathway across different malignancies: A new perspective","volume":"120","author":"Burotto","year":"2014","journal-title":"Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5826\/dpc.0901a13","article-title":"BRAF mutation status in primary, recurrent, and metastatic malignant melanoma and its relation to histopathological parameters","volume":"9","author":"Spathis","year":"2019","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.humpath.2014.04.001","article-title":"Molecular pathology of malignant melanoma: Changing the clinical practice paradigm toward a personalized approach","volume":"45","author":"Bradish","year":"2014","journal-title":"Hum. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","article-title":"Mechanical acts RAF-Erk signal pathway by oncological mutations B-Raf","volume":"116","author":"Wan","year":"2004","journal-title":"Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): Updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: Long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): Primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF","volume":"140","author":"Heidorn","year":"2010","journal-title":"Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1105358","article-title":"RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors","volume":"366","author":"Su","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1158\/0008-5472.CAN-07-6787","article-title":"Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma","volume":"68","author":"Montagut","year":"2008","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.21037\/atm.2017.06.09","article-title":"Overcoming resistance to BRAF inhibitors","volume":"5","author":"Arozarena","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"77163","DOI":"10.18632\/oncotarget.12848","article-title":"Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance","volume":"7","author":"Raaijmakers","year":"2016","journal-title":"Oncotarget"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/1055-9965.EPI-06-1038","article-title":"Number of Nevi and Early-Life Ambient UV Exposure Are Associated with BRAF-Mutant Melanoma","volume":"16","author":"Thomas","year":"2007","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_29","unstructured":"Network, N.C.C. (2020, March 02). Cutaneous Melanoma. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma_blocks.pdf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jaad.2015.02.1113","article-title":"Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma","volume":"72","author":"Kim","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/jdv.14028","article-title":"Association between dermoscopic and reflectance confocal microscopy features of cutaneous melanoma with BRAF mutational status","volume":"31","author":"Bombonato","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/sj.jid.5700632","article-title":"Distinct Clinical and Pathological Features Are Associated with the BRAFT1799A(V600E) Mutation in Primary Melanoma","volume":"127","author":"Liu","year":"2007","journal-title":"J. Investig. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jaad.2017.12.064","article-title":"The association between dermoscopic features and BRAF mutational status in cutaneous melanoma: Significance of the blue-white veil","volume":"78","author":"Nagore","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/bjd.13069","article-title":"Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma","volume":"171","author":"Pozzobon","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/jid.2012.283","article-title":"BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma","volume":"133","author":"Mann","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/bjc.2016.44","article-title":"BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival","volume":"114","author":"Hugdahl","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ctrv.2018.09.005","article-title":"Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine","volume":"71","author":"Tarhini","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2019.11.016","article-title":"Update on tolerability and overall survival in COLUMBUS: Landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600\u2013mutant melanoma","volume":"126","author":"Ascierto","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"367","DOI":"10.6004\/jnccn.2019.0018","article-title":"Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Coit","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_40","first-page":"24","article-title":"Impact of BRAF mutation status in the prognosis of cutaneous melanoma: An area of ongoing research","volume":"3","author":"Bhatia","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/1078-0432.CCR-10-2276","article-title":"Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma","volume":"17","author":"Ellerhorst","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/bjd.13521","article-title":"BRAF, NRAS and MC 1R status in a prospective series of primary cutaneous melanoma","volume":"172","author":"Traves","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.cllc.2020.05.007","article-title":"Clinical Utility of Reflex Ordered Testing for Molecular Biomarkers in Lung Adenocarcinoma","volume":"21","author":"Anand","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"ref_45","unstructured":"The Society of Gynecologic Oncology of Canada (2021, March 02). Why is Tumour Testing in Ovarian Cancer Needed in Canada? An Opinion Statement Developed by the National BRCA Collaborative. Available online: http:\/\/g-o-c.org\/wp-content\/uploads\/2020\/02\/20BRCACollaborative_TumourTestinginCanada_FINAL_Jan30.pdf."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Michielin","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2217\/mmt-2019-0022","article-title":"Epidemiology and survival outcomes in stages II and III cutaneous melanoma: A systematic review","volume":"7","author":"Miller","year":"2020","journal-title":"Melanoma Manag."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/CMR.0000000000000483","article-title":"Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patients","volume":"29","author":"Tan","year":"2019","journal-title":"Melanoma Res."},{"key":"ref_49","unstructured":"Normanno, N. (2021, April 23). BRAF in Melanoma: ESMO Biomarker Factsheet. Available online: https:\/\/oncologypro.esmo.org\/education-library\/factsheets-on-biomarkers\/braf-in-melanoma."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/modpathol.2017.104","article-title":"Molecular testing for BRAF mutations to inform melanoma treatment decisions: A move toward precision medicine","volume":"31","author":"Cheng","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"630","DOI":"10.2340\/00015555-2326","article-title":"Highly Concordant Results Between Immunohistochemistry and Molecular Testing of Mutated V600E BRAF in Primary and Metastatic Melanoma","volume":"96","author":"Manfredi","year":"2016","journal-title":"Acta Derm. Venereol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Ihle, M.A., Fassunke, J., K\u00f6nig, K., Gr\u00fcnewald, I., Schlaak, M., Kreuzberg, N., Tietze, L., Schildhaus, H.-U., B\u00fcttner, R., and Merkelbach-Bruse, S. (2014). Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAFmutations. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-13"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.5858\/arpa.2011-0505-OA","article-title":"Multisite Analytic Performance Studies of a Real-Time Polymerase Chain Reaction Assay for the Detection of BRAF V600E Mutations in Formalin-Fixed, Paraffin-Embedded Tissue Specimens of Malignant Melanoma","volume":"136","author":"Anderson","year":"2012","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jmoldx.2012.09.001","article-title":"Detection of BRAF p.V600E Mutations in Melanomas","volume":"15","author":"Colomba","year":"2013","journal-title":"J. Mol. Diagn."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Mancini, I., Simi, L., Salvianti, F., Castiglione, F., Sonnati, G., and Pinzani, P. (2019). Simi Analytical Evaluation of an NGS Testing Method for Routine Molecular Diagnostics on Melanoma Formalin-Fixed, Paraffin-Embedded Tumor-Derived DNA. Diagnostics, 9.","DOI":"10.3390\/diagnostics9030117"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/CMR.0000000000000421","article-title":"Rapid BRAF mutation tests in patients with advanced melanoma: Comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform","volume":"28","author":"Bisschop","year":"2018","journal-title":"Melanoma Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.5858\/133.10.1600","article-title":"The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer","volume":"133","author":"Ogino","year":"2009","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2353\/jmoldx.2010.090188","article-title":"Comparison of Sanger Sequencing, Pyrosequencing, and Melting Curve Analysis for the Detection of KRAS Mutations: Diagnostic and Clinical Implications","volume":"12","author":"Tsiatis","year":"2010","journal-title":"J. Mol. Diagn."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.yexmp.2015.09.004","article-title":"Multi-center evaluation of the novel fully-automated PCR-based Idylla\u2122 BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma","volume":"99","author":"Melchior","year":"2015","journal-title":"Exp. Mol. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1038\/srep04168","article-title":"High-Resolution Melting Analysis for accurate detection of BRAF mutations: A systematic review and meta-analysis","volume":"4","author":"Chen","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3389\/fmolb.2020.00113","article-title":"The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape","volume":"7","author":"Vanni","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jmoldx.2013.07.003","article-title":"Detection of BRAF V600 Mutations in Metastatic Melanoma","volume":"15","author":"Qu","year":"2013","journal-title":"J. Mol. Diagn."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3747\/co.24.3266","article-title":"Rate of Egfr Mutation Testing for Patients with Nonsquamous Non-Small-Cell Lung Cancer with Implementation of Reflex Testing by Pathologists","volume":"24","author":"Cheema","year":"2017","journal-title":"Curr. Oncol."},{"key":"ref_64","first-page":"193","article-title":"Prognostic factors in 1521 melanoma patients with distant metastases","volume":"181","author":"Barth","year":"1995","journal-title":"J. Am. Coll. Surg."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41591-019-0448-9","article-title":"Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma","volume":"25","author":"Ascierto","year":"2019","journal-title":"Nat. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e720","DOI":"10.1016\/S1470-2045(18)30596-5","article-title":"Adjuvant melanoma therapy with new drugs: Should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?","volume":"19","author":"Grob","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2017.74.1025","article-title":"Long-Term Outcomes in Patients With BRAF V600\u2013Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib","volume":"36","author":"Long","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3322\/caac.21560","article-title":"The current state of molecular testing in the treatment of patients with solid tumors, 2019","volume":"69","author":"Goldberg","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1634\/theoncologist.2018-0154","article-title":"Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria","volume":"24","author":"Natsuhara","year":"2018","journal-title":"Oncologist"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Katz, G., Romano, O., Foa, C., Vataire, A.-L., Chantelard, J.-V., Herv\u00e9, R., Barletta, H., Durieux, A., Martin, J.-P., and Salmon, R. (2015). Economic Impact of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in France. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0128880"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e815","DOI":"10.1200\/JOP.2017.023788","article-title":"Implementation of Surgeon-Initiated Gene Expression Profile Testing (Oncotype DX) Among Patients With Early-Stage Breast Cancer to Reduce Delays in Chemotherapy Initiation","volume":"13","author":"Losk","year":"2017","journal-title":"J. Oncol. Pract."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3747\/co.v18i4.779","article-title":"Canadian Expert Group Consensus Recommendations: KRAS Testing in Colorectal Cancer","volume":"18","author":"Aubin","year":"2011","journal-title":"Curr. Oncol."},{"key":"ref_75","unstructured":"Giri, V. (2021, March 02). New Recommendations Offer Guidance for Clinicians and Patients on Genetic Testing for Prostate Cancer. Available online: https:\/\/ascopost.com\/issues\/july-10-2020\/new-recommendations-offer-guidance-for-clinicians-and-patients-on-genetic-testing-for-prostate-cancer\/."},{"key":"ref_76","unstructured":"Laboratories, M.C. (2020, September 01). BCR\/ABL1 Qualitative Diagnostic Assay with Reflex to BCR\/ABL1 p190 Quantitative Assay or BCR\/ABL1 p210 Quantitative Assay, Varies. Available online: https:\/\/www.mayocliniclabs.com\/test-catalog\/Overview\/65248."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41379-019-0447-x","article-title":"Detection of the KITD816V mutation in myelodysplastic and\/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis","volume":"33","author":"Craig","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_78","unstructured":"Assasi, N., Blackhouse, G., Campbell, K., Weeks, L., and Levine, M. (2015). Mismatch Repair Deficiency Testing for Patients with Colorectal Cancer: A Clinical and Cost-Effectiveness Evaluation, CADTH."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1097\/PAS.0000000000000321","article-title":"Lynch Syndrome Screening Should Be Considered for All Patients With Newly Diagnosed Endometrial Cancer","volume":"38","author":"Mills","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"559","DOI":"10.5858\/arpa.2017-0286-CP","article-title":"Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists","volume":"142","author":"Lewis","year":"2017","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Smith, A.L., Wong, C., Cuggia, A., Borgida, A., Holter, S., Hall, A., Connor, A.A., Bascu\u00f1ana, C., Asselah, J., and Bouganim, N. (2018). Reflex Testing for Germline BRCA1, BRCA2, PALB2, and ATM Mutations in Pancreatic Cancer: Mutation Prevalence and Clinical Outcomes From Two Canadian Research Registries. JCO Precis. Oncol., 1\u201316.","DOI":"10.1200\/PO.17.00098"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"v126","DOI":"10.1093\/annonc\/mdv297","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Dummer","year":"2015","journal-title":"Ann. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/9\/2282\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:58:53Z","timestamp":1760162333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/9\/2282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,10]]},"references-count":82,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["cancers13092282"],"URL":"https:\/\/doi.org\/10.3390\/cancers13092282","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,10]]}}}